Figure 7.

CXCR2 Blockade Promotes T Cell Infiltration into Tumors and Sensitivity to Immunotherapy

(A) Kaplan-Meier survival analysis of tumor-bearing KPC mice treated with either gemcitabine, CXCR2 SM alone for 2 weeks, and then in combination with anti-PD1, vehicle alone for 2 weeks, and then combined with anti-PD1, CXCR2 SM alone (censors on pink line), or vehicle alone (censors on cyan line). Few mice on vehicle alone survived for 2 weeks to allow PD1 treatment as shown in the table below. p Values, chi-square test.

(B and C) IHC for Ki67 in tumors from KPC mice treated with (B) vehicle + PD1 or (C) CXCR2 SM + PD1.

(D and E) IHC for cleaved caspase 3 in tumors from KPC mice treated with (D) vehicle + PD1 or (E) CXCR2 SM + PD1.

(F) FACS analysis of intratumoral CD3⁺ cells in mice treated as indicated.

(G) Boxplot showing quantification of IHC for CD4⁺ and CD8⁺ T cells in tumors from KPC mice treated as indicated.

(H) FACS analysis of intratumoral CD4⁺, CD8⁺, CD4⁺CD25⁺, and NK1.1⁺ cells (% of CD3⁺ cells) in mice treated as indicated.

(I) FACS profile of CD4⁺ and CD8⁺ T cells isolated from tumors in mice treated with either vehicle + anti-PD1 or CXCR2 SM + anti-PD1. (F–I) n = 3. p Values, Mann-Whitney U test.